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Background: Exacerbations are a major risk and a cause of asthma morbidity and healthcare
utilization. Viral-induced upper respiratory tract infections are the most frequent trigger of
asthma-related exacerbations. Studies have traditionally assessed exacerbations without
documentation regarding exacerbation etiology. Therefore, it remains unknown whether
asthma medications can alter exacerbation susceptibility based on a specific etiology.
Objective: To examine whether treatment with inhaled corticosteroids plus long-acting beta2-
agonists reduced the number of exacerbations associated with upper respiratory tract infec-
tions versus inhaled corticosteroids alone.
Methods: Two large datasets comparing treatment with fluticasone propionate and fluticasone
propionate plus salmeterol were analyzed, including the number of clinically reported upper
respiratory tract infections, asthma-related exacerbations, and the presence of an exacerba-
tion and concurrent report of an upper respiratory tract infection.
Results: Both treatment groups had similar incidences of upper respiratory tract infections. Of
those reporting an upper respiratory tract infection, statistically significantly fewer reported
an asthma-related exacerbation comparing fluticasone propionate plus salmeterol with flutica-
sone propionate (pZ 0.0057).
Discussion: This retrospective analysis suggests that therapy with fluticasone propionate plus
salmeterol provides protection against asthma exacerbations temporally associated with upper
respiratory tract infections. This retrospective analysis supports the hypothesis that specificAMP, Childhood Asthma Management Program; FP, fluticasone propionate; GOAL, Gaining Optimal
steroids; LABA, long-acting beta agonist; NHLBI, National Health Lung and Blood Institute; PEAK,
T, randomized clinical trials; RV, rhinovirus; SAL, salmeterol; URTI, upper respiratory tract infection.
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Well-controlled prospective studies are warranted.
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Common viral upper respiratory tract infections (URTIs) are
widely recognized as a frequent and major precipitator of
asthma exacerbations.1e4 Rhinoviruses (RVs) have been
identified as the major contributor to asthma exacerbations
in both children and adults.5e8 In fact, RVs may account for
up to two-thirds of the virus detected during an exacer-
bation of asthma.9e11 Rhinoviruses are commonly associ-
ated with the common cold and are the most predominant
cause of respiratory illness in children in the early fall.9
Coincidently, the beginning of the school year also marks
the beginning of the epidemic season for asthma-related
hospitalizations1,12e14 Increases in asthma exacerbations
in adults appear to follow soon after the childhood peaks.
The Childhood Asthma Management Program (CAMP) and
the Prevention of Early Asthma in Kids (PEAK) studies both
demonstrated a statistically significant decrease in severe
exacerbations of asthma associated with patients using
inhaled corticosteroids compared to placebo.15,16 Reduc-
tions in exacerbations have been also documented in
observational studies and meta-analysis have demonstrated
a greater reduction in severe exacerbations associated with
the use of inhaled corticosteroids (ICS) and long-acting beta
agonists (LABA) when compared to an ICS alone.1,17
Although most studies do not specifically address exacer-
bations triggered by viral URTIs, if approximately 80% of
exacerbations are virally triggered as suggested by the
literature,3,13,18 and exacerbation reductions in studies
examining controller medications, such as CAMP are 40e
45%, then the use of asthma controllers may be impacting
the incidence of virally induced exacerbations. Therefore,
a body of clinical evidence suggests that treatment aimed
at promoting asthma control may reduce a subject’s risk for
experiencing an asthma exacerbation. Since the majority of
asthma exacerbations are the result of viral infections, and
predominantly RV infections, then logically the next ques-
tion to pose is whether treatment with ICS or ICSþ LABA
further reduces the number of asthma exacerbations
associated with upper respiratory tract infections (URTIs).
Clinical trials typically do not type viruses associated
with adverse events or asthma exacerbations, however,
descriptive information regarding adverse events and
exacerbations are collected and include terms such as
‘‘common cold’’ or ‘‘upper respiratory tract infection’’.
While the term ‘‘common cold’’ does not specify viral
etiology, it is well established that viruses and particularly
RV is a highly prevalent candidate as the etiological agent
of the common cold in children above 3 years of age and in
adults.5,9,10
The objective of this retrospective analysis was to
examine whether treatment with fluticasone propionate
(FP)þ salmeterol (SAL), in adolescent and adult subjects
with moderate persistent asthma, would reduce the
number of subjects who experience asthma exacerbationsassociated with a concurrent URTI when compared to
treatment with FP alone. For this analysis, an exacerbation
was considered to be possibly related to a URTI if the
investigator recorded the cause of event by a diagnostic
category likely to be associated with an UTRI. The results
presented here support this hypothesis and further high-
light the need for definitive prospective studies in subjects
with persistent asthma of all ages to confirm this thera-
peutic benefit and to identify the mechanistic basis for this
effect.Methods
Study selection and data extraction
The analysis population included data from clinical studies in
the GlaxoSmtihKline US Asthma Database, a data repository
for clinical trials conducted with the following GlaxoSmithK-
line therapies; fluticasone propionate/salmeterol (Advair),
salmeterol (Serevent), and fluticasone propionate (Flo-
vent). All studies included in the analysis were randomized,
double blinded, parallel group studies with subjects well
matched among the studies for baseline demographics (Table
1). Subjects consisted of adolescences or adults treated prior
to screening with low to moderate doses of inhaled cortico-
steroids. The data for 8 clinical studies that contained treat-
ment arms of FP and SAL were pooled for analysis (RCTs;
SAS40024; SAS40025; SAS40036; SAS40037, SLGA5021;
SLGA5022, FLTA4021; and FLTA4022; nZ 2424). In addition
data were assessed from the Gaining Optimal Asthma controL
study (GOAL; SAM40027; nZ 3416) database. Five of the 9
studies provided FP and SAL in a single device (SAS40024;
SAS40025; SAS40036; SAS40037, SAM40027) while the other 4
studies dispensed the study drugs via separate metered dose
inhalers (SLGA5021; SLGA5022; FLTA4021; FLTA4022). Details
regarding study design of each of the 9 studies have been
previously published19e23 and additional study summary
information for each of these studies can be found on the
GlaxoSmithKline Clinical Study Register (http://www.gsk-
clinicalstudyregister.com/index.jsp).
Data regarding the incidence of asthma exacerbations
and URTIs were extracted for all studies included in this
analysis. In the GOAL study (SAM40027), exacerbations
were defined as the need for oral corticosteroid use, and/or
emergency department visit, and/or hospitalization. In the
RCTs, exacerbations included the above criteria and/or the
use of additional non-study medications for the treatment
of asthma. Identification of a URTI included any adverse
event coded as the following: cold symptoms, common
cold, head cold, viral pharyngitis, viral sore throat, respi-
ratory tract infection, respiratory infection, respiratory
tract infection no other source (NOS), respiratory tract
infection viral, respiratory tract infection viral NOS, influ-
enza, influenza A virus infection, infective rhinitis, upper
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782 C.M. Prazma et al.respiratory tract infection, upper respiratory tract infec-
tion bacterial, viral upper respiratory tract infection, viral
rhinitis.
Statistical analysis
The occurrence of a reported asthma exacerbation was
collected independently of reported adverse events. An
exacerbation was declared to be associated with a URTI if
the exacerbation occurred at any point in time during the
duration of a URTI or if the exacerbation started within 7
days of the reported cessation of a URTI. Summary statistics
by treatment group for the number of events and number of
subjects with an event were generated. Assessment of
statistical significance for the number of subjects with an
event between treatment groups was based on a 2-sided
Fisher’s exact test. Statistical significance was defined at
the 0.05 level.
Results
URTI and asthma associated exacerbations in GOAL
and RCT study populations
The incidence of URTIs, recorded as adverse events (AEs),
and asthma exacerbations were examined retrospectively
in the two large, distinct clinical databases (GOAL and
RCTs) as individual and combined datasets. Analysis of the
individual and combined datasets demonstrated that
infectious exposures and subsequent URTIs were similar
between treatment groups. Approximately, 31% of subjects
reported a URTI irrespective of treatment group (Table 2).
In the GOAL analysis, 30% of those treated with FP mono-
therapy and 30% of those treated with FPþ SAL combina-
tion therapy reported a URTI. In the RCT analysis, 31% of
those treated with FP monotherapy and 32% of those
treated with FPþ SAL combination therapy reported a URTI
(Fig 1A). There was no statistically significant difference in
the number of subjects reporting a URTI between subjects
receiving FP monotherapy or FPþ SAL combination therapy
treatment in both the GOAL (pZ 0.88) and RCT studies
(pZ 0.76; Table 2).
The number of asthma exacerbations in the GOAL, RCT,
and combined clinical databases was lower among subjects
treated with combination therapy when compared to the
incidence of exacerbations in subjects treated with ICS
monotherapy (Table 3). Of the subjects treated with FP
monotherapy in the GOAL study, 15.3% reported an exac-
erbation whereas statistically significantly fewer subjects
treated with FPþ SAL combination therapy reported an
exacerbation (10.4%; p< 0.0001; Fig. 1B). Similarly, in the
RCT database, 9.3% of the subjects receiving FP mono-
therapy reported an exacerbation whereas only 5.0% of the
subjects receiving FPþ SAL combination therapy reported
an exacerbation (Fig. 1B; p< 0.0001). Of the subjects
treated with FP monotherapy in the combined analysis,
12.9% reported an exacerbation whereas 8.1% of the
subjects receiving FPþ SAL combination therapy reported
an exacerbation (Table 2).
The incidence of asthma exacerbations associated with
URTIs was also examined in the individual and combined
Table 2 Number of subjects with URTIs and/or exacerbations.
Number of subjects GOAL RCTs Combined
FPþ SAL
(nZ 1709)
FP
(nZ 1707)
FPþ SAL
(nZ 1232)
FP
(nZ 1192)
FPþ SAL
(nZ 2941)
FP
(nZ 2899)
With an exacerbation 178*** 262 61*** 111 239 373
With a URTI 513 517 393 373 906 890
aWith a URTI and any
exacerbation
80** 118 41* 61 121 179
aWith a URTI and
a concurrent
exacerbation
47 60 28* 50 75* 110
*p< 0.05; **p< 0.005; ***p< 0.0001.
a The statistical testing was based on the number of subjects with a URTI.
Figure 1 Incidence of URTIs, exacerbations, or exacerbations associated with URTIs in the GOAL and RCT study populations.
(A) The percentage of subjects reporting URTIs was similar between each treatment arm in both the RCT and GOAL datasets. The
results represent the percentage of subjects among each study treatment arm (FPþ SAL versus FP) that reported a URTI.
(B) Decreased percentage of subjects reporting one or more exacerbations among subjects treated with FPþ SAL combination
therapy when compared to FP monotherapy. The results represent the percentage of subjects among each treatment arm (FPþ SAL
versus FP) that reported one or more exacerbations, results are shown for each dataset. (C) Decreased percentage of subjects with
exacerbations associated with URTIs among subjects treated with FPþ SAL combination therapy when compared to FP mono-
therapy. The results represent the percentage of subjects among each treatment arm (FPþ SAL versus FP) that reported an
exacerbation within 7 days of the start/stop date of the URTI. (D) Decreased percentage of subjects with exacerbations associated
with URTIs among subjects treated with FPþ SAL combination therapy when compared to FP monotherapy. The results represent
the percentage of subjects among each treatment arm (FPþ SAL versus FP) in the combined RCT and GOAL dataset that reported
an exacerbation within 7 days of the start/stop date of the URTI.
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Table 3 Total number of URTIs AEs or exacerbation events.
GOAL RCTs Combined
FPþ SAL
(nZ 1709)
FP
(nZ 1707)
FPþ SAL
(nZ 1232)
FP
(nZ 1192)
FPþ SAL
(nZ 2941)
FP
(nZ 2899)
Number of exacerbations 258 351 70 127 328 478
Number of URTIs 854 924 547 509 1401 1433
Number of exacerbations
for subjects with a URTI
131 163 47 72 178 235
Number of URTIs with
a concurrent an exacerbation
61 82 31 51 92 133
784 C.M. Prazma et al.datasets. In both the GOAL and RCT datasets the incidence
of exacerbations associated with URTIs was lowest among
subjects receiving FPþ SAL combination therapy when
compared to those receiving FP alone (Table 2). In the
GOAL study, of the subjects reporting a URTI and treated
with FP, 11.6% of the subjects had an exacerbation asso-
ciated with a URTI, while 9.2% of the subjects reporting
a URTI and treated with FPþ SAL had an exacerbation
associated with a URTI (Fig. 1C, pZ 0.22). In the RCT
studies, of the subjects reporting a URTI and treated with
FP, 13.4% of the subjects had an exacerbation associated
with a URTI, while only 7.1% of subjects reporting a URTI
and treated with FPþ SAL had an exacerbation associated
with a URTI (pZ 0.006). In the RCT studies, this corre-
sponds to a 47% reduction in the number of subjects with an
exacerbation associated with URTIs in the FPþ SAL combi-
nation therapy group versus the FP monotherapy group
(Fig. 1C). Likewise, while 12.4% of subjects experiencing
a URTI and receiving FP treatment within the combined
dataset experienced an exacerbation associated with
a URTI, statistically significantly fewer subjects with a URTI
and treated with FPþ SAL reported a URTI and concurrent
exacerbation, a 33% greater reduction with the combina-
tion of controllers (8.3%, pZ 0.005; Fig. 1D).
Discussion
Exacerbations of asthma associated with viral infections are
a major contributor of morbidity and healthcare utilization
associated with this disease.24e28 Several studies have
demonstrated that the use of ICS as maintenance therapy
reduces the incidence of exacerbations in both children and
adults.29e31 The childhood asthma management program
(CAMP) demonstrated that chronic treatment of asthma
with ICS significantly reduced the risk of exacerbations
including the need for oral corticosteroids, urgent care
visits, or hospitalizations, by approximately 40e45%.15
Although CAMP did not directly demonstrate a reduction
in worsening asthma caused by viral infection or URTIs, the
fact that the literature reports that a significant proportion
of asthma exacerbations are triggered by viruses would
suggest that many of these illnesses were mitigated by the
use of maintenance budesonide. In community based
studies, school age children who presented to emergency
departments with worsening asthma in the fall season were
significantly less likely to have reported use of inhaled
corticosteroids and were more likely to have a respiratoryvirus when compared to a case-control group of children
with similar asthma severity.1,10,11
Studies examining the addition of LABA to ICS compared
with a similar or higher dose ICS alone have shown that
combination therapy results in a statistically significant
reduction in the risk of an asthma exacerbation compared
to ICS monotherapy.17,32,33 The retrospective analysis pre-
sented here suggests that the use of combination therapy
(FPþ SAL) reduces the incidence of asthma exacerbations
more than treatment with FP monotherapy, and that
combination therapy also reduces the incidence of exac-
erbations of asthma that are associated with URTIs in adults
and adolescents. The data presented demonstrate a trend
in each dataset (GOAL analysis, RCT analysis, and
combined) towards a reduction in the number of adolescent
and adult subjects presenting with a URTI and a concurrent
exacerbation when treated with FPþ SAL versus FP
monotherapy.
The exact mechanisms regarding how ICS and ICSþ LABA
protect from exacerbations is not fully known however
prevention of epithelial damage and preservation of airway
epithelial wall integrity may be two key components.
Inhaled corticosteroids reduce damage to the epithelium
that occurs as a result of cytokines and inflammatory
mediators that are secreted by infiltrating leukocytes.34,35
More specifically, ICS act by potently suppressing epithe-
lial release of cytokines and chemoattractants that
promote the recruitment, survival, and activation of T
cells, eosinophils, and other effector cells.36,37 Further-
more, the use of ICS promotes epithelial integrity indirectly
through reversing the release of mediators, such as TNFa,
which decrease the expression of adhesion molecules that
are required for the maintenance of proper cell-cell
adhesion.36,38
Combination therapy (ICSþ LABA) provides an even
greater reduction in exacerbations (Fig. 1B) and in exac-
erbations that present with a concurrent URTI (Fig. 1C)
when compared with treatment with ICS monotherapy.
While the exact mechanism for why the addition of LABAs
to ICS controller medication might reduce the risk of
exacerbation has not been completely defined, evidence
suggests that LABAs may provide direct protection to the
respiratory epithelium. The preservation of the structural
integrity of the respiratory epithelium depends on the
formation and maintenance of tight junctions. Important
components that contribute to the stability of epithelial
tight junctions are the Zonula occludens (ZO) proteins and
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E-cadherin.39,40 Salmeterol, a LABA, induces the endoge-
nous expression of ZO-1 and protects against bacterial toxin
induced degradation of ZO-1.41e43 Salmeterol also protects
against the disruption of epithelial integrity caused by
histamine, a key component of allergic inflammation.
Histamine can specifically cause the disruption of E-cad-
herin.44 Pretreatment of airway epithelium or E-cadherin
expressing L cells with salmeterol prevents histamine
receptor activation and the interruption of E-cadherin
adhesion.45 Previous studies have also shown that in addi-
tion to the bronchodilatory effect and protection of tight
junctions, salmeterol protects against reduced ciliary beat
function induced by infection.46 Thus, LABAs may not only
act in combination with ICS to synergistically prevent the
damage that ensues as a result of the inflammatory
response, LABAs may also act to protect against the
disruption of epithelial tight junctions, preventing alter-
ation to airway epithelial tightness and permeability of the
epithelial barrier.
Rhinoviruses (RVs) are the major cause of respiratory
infections and it has been long recognized that seasonal
peaks in RV correlate with hospital admissions due to
asthma.1,13,14,47 Airway epithelial cells are the major site of
RV infection and replication however, a recent study
demonstrated that basal cells, as opposed to more super-
ficial epithelial cells, express higher levels of ICAM-1 and
are thus more susceptible to RV.48e50 The implication of this
finding is that damaged epithelium could allow RV easier
access to the more susceptible layer of basal cells. Thus, an
asthmatic with sustained epithelial damage may be more
susceptible to RV infection, replication and subsequently
more likely to exacerbate upon RV exposure. Additionally,
a recent study by Sajjan et al. demonstrated that RV
replication in epithelial cells results in the redistribution of
ZO-1 causing disruption to tight junctions.51 In an in vitro
study of epithelial damage, RV infection also diminished
the self-repairing capacities of bronchial epithelial cells.52
Together these findings provide not only an explanation as
to why RV infection is the major viral initiator of asthma
exacerbation but also provides support for a mechanistic
role of LABAs in the protection and preservation of the
epithelial integrity and subsequently in the reduction of
asthma exacerbations.
Traditionally, it has been hypothesized that anti-
inflammatory maintenance therapies reduce the risk of
asthma exacerbation by altering the immune and inflam-
matory environment present in the asthmatic airway.
However, recent data support the hypothesis that the use
of combination controller medication (ICSþ LABA) protects
and preserves the airway epithelium. The protection and
preservation of the airway epithelium may be particularly
important in reducing the risk of exacerbation caused
specifically by RVs. This is potentially of major significance
as it is well established that RV is responsible for nearly 80%
of the exacerbations that occur in children and nearly 50%
of the exacerbations that occur in adults.3,13,18 While
extrapolation of the data presented here is limited by the
fact that the study population consisted only of adolescent
and adult subjects and because viral etiology was not
clinically determined, these data add support to this
theory. Furthermore, although the studies presented herewere of varying durations and were heterogeneous in
nature with respect to the run-in period, the results were
consistent with between the datasets analyzed (GOAL and
RCT) and were consistent with the results currently present
in the literature regarding an association between a reduc-
tion of exacerbations and controller medication use. These
results are further supported by a recent observational
study that confirms the importance of the use of mainte-
nance controller medication and supports the hypothesis
that controller medication protects and preserves the
epithelial integrity.53 Spahn et al. demonstrated that
dispensing of controller medication during a season was
associated with a decreased risk of asthma-related emer-
gency department visits and hospitalizations in the subse-
quent season. This effect was noted in all age groups
studied, including children and adults. This is in contrast to
a lack of risk reduction when patients were dispensed their
controller medication during only the current season.
These findings are limited by the fact the definition of an
exacerbation was not consistent across each study,
however for the purposes of this analysis it was established
that the definition of an exacerbation used in each of these
studies reflected a state of worsening asthma and is
consistent with definitions used in clinical practice. The
findings are also limited by the lack of specific viralogical
assessment at the time of the exacerbation. The associa-
tions with respiratory tract infections are instead based
a retrospective analysis of data and point to the need for
future studies to incorporate better understanding of the
etiology of exacerbations. Recent advances in technology
provide a greater ability to diagnose the viral etiology of
asthma exacerbation and thus it is now possible to design
prospective clinical studies to confirm the observation that
FPþ SAL combination therapy have a protective role in the
prevention of viral-induced exacerbations.
In conclusion, protecting and preserving epithelial
integrity is of importance in asthmatics especially consid-
ering asthmatics with damaged respiratory epithelium may
be more susceptible to RV infection, the major viral
contributor associated with asthma exacerbation. The
results of this analyses suggest that two common controller
therapies, inhaled corticosteroids and long-acting beta
agonists, when used in combination may have a protective
effect in reducing viral-induced exacerbations in subjects
with moderate persistent asthma and that this effect may
be greater than ICS monotherapy.
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